INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17201, 'Hydrochlorothiazide', 'Oxybutynin', 'Minor', 'Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17216/', '', 'Trandolapril, Moexipril, Olmesartan, Azilsartan medoxomil, Candesartan, Eprosartan, Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Mirabegron, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17202, 'Hydrochlorothiazide', 'Oxycodone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17217/', '', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', 'Trichlormethiazide, Methyclothiazide, Sacubitril, Aliskiren, Trichlormethiazide, Aliskiren, Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, Methazolamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17203, 'Hydrochlorothiazide', 'Oxytetracycline', 'Minor', 'The coadministration of diuretics and tetracyclines may result in decreased renal function manifested by increases in serum creatinine and blood urea nitrogen (BUN). Usually, no clinical intervention is necessary, unless decreases in renal function occur. If renal function deteriorates, discontinuation of one or both agents may be necessary.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17218/', '', 'Sarecycline, Ganciclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Lomefloxacin, Sulfamethizole, Trifluridine, Benzylpenicillin, Ampicillin, More', 'Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Lisinopril, Perindopril, Bisoprolol, Benazepril, Trandolapril, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17204, 'Hydrochlorothiazide', 'Ozanimod', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17219/', '', 'Sacubitril, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, More', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Upadacitinib, Siponimod, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17205, 'Hydrochlorothiazide', 'Paliperidone', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.', 'DDInter', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17220/', '', 'Sacubitril, Aliskiren, Aliskiren, Tamsulosin, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Pimavanserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17206, 'Hydrochlorothiazide', 'Pancuronium', 'Moderate', 'Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.', 'DDInter', 'Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17221/', '', 'Moexipril, Perindopril, Benazepril, Quinapril, Trandolapril, Fosinopril, Valsartan, Irbesartan, Losartan, Olmesartan, Azilsartan medoxomil, More', 'Botulinum toxin type A', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17207, 'Hydrochlorothiazide', 'Pantoprazole', 'Moderate', 'Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that can cause magnesium loss. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. Hypomagnesemia can also cause impaired parathyroid hormone secretion, which may lead to hypocalcemia. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the FDA, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI.', 'DDInter', 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.', 'Synergism', 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17222/', '', 'Tinidazole, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin', 'Trandolapril, Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Eprosartan, Tinidazole, Ascorbic acid, Simeprevir, Lactic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17208, 'Hydrochlorothiazide', 'Paraldehyde', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17223/', '', 'Felodipine, Trichlormethiazide, Sacubitril, Aliskiren, Trichlormethiazide, Aliskiren, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, More', 'Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17209, 'Hydrochlorothiazide', 'Paricalcitol', 'Moderate', 'Coadministration of thiazide diuretics with high dosages of calcium and/or vitamin D has been associated with reports of hypercalcemia in some patients. Thiazide diuretics inhibit the renal excretion of calcium and may also enhance responsiveness of bone and renal tubule to parathyroid hormone, thus concurrent use of large amounts of calcium or vitamin D can lead to excessively high plasma levels of calcium. Patients who are particularly susceptible include those with hyperparathyroidism, those being treated for osteoporosis, and those receiving high dosages of vitamin D for hypoparathyroidism. Metabolic alkalosis and the milk-alkali syndrome have been reported during prolonged therapy with thiazide diuretics and calcium.', 'DDInter', 'Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider. Serum calcium should be monitored if thiazide diuretics are coadministered with high dosages of calcium and/or vitamin D. Patients should be advised to seek medical attention if they experience signs and symptoms of hypercalcemia such as dizziness, weakness, lethargy, headache, myalgia, anorexia, nausea, vomiting, and seizures.', 'Synergism', 'Patients receiving thiazide diuretic therapy should be cautioned against self-treatment with calcium and vitamin D supplements without first talking to their healthcare provider.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17224/', '', 'Etelcalcetide, Cinacalcet, Salmon calcitonin', 'Moexipril, Perindopril, Benazepril, Trandolapril, Fosinopril, Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17210, 'Hydrochlorothiazide', 'Paroxetine', 'Moderate', 'Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.', 'DDInter', 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17225/', '', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Trandolapril, Olmesartan, Azilsartan medoxomil, Candesartan, Eprosartan, Sacubitril, Aliskiren, Aliskiren, Tinidazole, Mitapivat, Ascorbic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17211, 'Hydrochlorothiazide', 'Pentazocine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17226/', '', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', 'Trichlormethiazide, Methyclothiazide, Sacubitril, Aliskiren, Trichlormethiazide, Aliskiren, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17212, 'Hydrochlorothiazide', 'Pentoxifylline', 'Moderate', 'Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.', 'DDInter', 'Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.', 'Synergism', 'Caution is advised if pentoxifylline is used in combination with hypotensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17227/', '', 'Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Omalizumab, Tezepelumab, Benralizumab, Caffeine, Reslizumab, Dyphylline, More', 'Sacubitril, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17213, 'Hydrochlorothiazide', 'Perphenazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.', 'DDInter', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17228/', '', 'Pimavanserin', 'Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17214, 'Hydrochlorothiazide', 'Phenelzine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17229/', '', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Sacubitril, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17215, 'Hydrochlorothiazide', 'Phenobarbital', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17230/', '', 'Trichlormethiazide, Methyclothiazide, Sacubitril, Aliskiren, Trichlormethiazide, Aliskiren, Ascorbic acid, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', 'Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17216, 'Hydrochlorothiazide', 'Phenolphthalein', 'Moderate', 'The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.', 'DDInter', 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Synergism', 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17231/', '', 'Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Lisinopril, Perindopril, Bisoprolol, Benazepril, Quinapril, More', 'Alvimopan, Sorbitol, Magnesium sulfate, Methylnaltrexone, Magnesium oxide, Naloxegol, Plecanatide, Lubiprostone, Methylcellulose, Mannitol, Naldemedine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17217, 'Hydrochlorothiazide', 'Phenylbutazone', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', 'DDInter', 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17232/', '', 'Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide', 'Felodipine, Amlodipine, Verapamil, Trichlormethiazide, Amlodipine, Sacubitril, Trichlormethiazide, Amlodipine, Tamsulosin, Tinidazole, Ascorbic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17218, 'Hydrochlorothiazide', 'Pimozide', 'Major', 'Pimozide can cause dose-related prolongation of the QT interval. While clinical data are lacking, the coadministration of pimozide and agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential.', 'DDInter', 'Caution is advised when pimozide must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with pimozide.', 'Synergism', 'Caution is advised when pimozide must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17233/', '', 'Felodipine, Enalapril, Amlodipine, Moexipril, Ramipril, Lisinopril, Perindopril, Bisoprolol, Benazepril, Quinapril, Trandolapril, More', 'Pimavanserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17219, 'Hydrochlorothiazide', 'Pindolol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', 'DDInter', 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17234/', '', 'Penbutolol, Esmolol, Carteolol, Penbutolol', 'Moexipril, Perindopril, Bisoprolol, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril, Irbesartan, Olmesartan, Azilsartan medoxomil, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17220, 'Hydrochlorothiazide', 'Pioglitazone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17235/', '', 'Trandolapril, Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Eprosartan, Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, More', 'Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17221, 'Hydrochlorothiazide', 'Pipecuronium', 'Moderate', 'Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.', 'DDInter', 'Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17236/', '', 'Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril, Trichlormethiazide, More', 'Botulinum toxin type A', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17222, 'Hydrochlorothiazide', 'Pirbuterol', 'Moderate', 'Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.', 'DDInter', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.', 'Synergism', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17237/', '', 'Felodipine, Moexipril, Perindopril, Benazepril, Trandolapril, Captopril, Fosinopril, Olmesartan, Azilsartan medoxomil, Telmisartan, Candesartan, More', 'Isoprenaline, Ephedrine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Ipratropium, Isoprenaline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17223, 'Hydrochlorothiazide', 'Piroxicam', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', 'DDInter', 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17238/', '', 'Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide, Fluocinolone acetonide, Salicylic acid, Fluorometholone', 'Sacubitril, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17224, 'Hydrochlorothiazide', 'Polyethylene glycol (3350)', 'Moderate', 'The chronic use or abuse of laxatives may potentiate the pharmacologic effects of diuretics. Laxatives can cause significant losses of fluid and electrolytes, including sodium, potassium, magnesium and zinc, and these effects may be additive to those of diuretics.', 'DDInter', 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages. During concomitant use with diuretics, patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia. If maintenance of bowel regularity is required, patients should be advised to exercise and increase fiber in the diet and/or consider the use of bulk-forming laxatives.', 'Synergism', 'In general, laxatives should only be used on a short-term, intermittent basis in recommended dosages.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17239/', '', 'Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Lisinopril, Perindopril, Bisoprolol, Benazepril, Quinapril, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17225, 'Hydrochlorothiazide', 'Polyethylene glycol (3350 with electrolytes)', 'Moderate', 'Coadministration with agents that affect renal function or perfusion such as diuretics, ACE inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk and/or severity of fluid and electrolyte disturbances associated with the use of bowel cleansing preparations. Fluid and electrolyte disturbances can lead to serious adverse events including cardiac arrhythmias, seizures, and renal impairment.', 'DDInter', 'Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment. Baseline and postprocedure labs including serum electrolytes, BUN, and creatinine should be considered. Patients should be advised to drink sufficient quantities of clear fluids before, during, and after bowel cleansing. Hospitalization and intravenous fluid hydration may be appropriate for frail or elderly patients who may be unable to drink an adequate volume of fluid.', 'Synergism', 'Caution is advised when bowel cleansing preparations are used in patients treated with agents that affect renal function or perfusion, particularly if they are frail or elderly or have preexisting renal impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17240/', '', 'Felodipine, Amlodipine, Verapamil, Bisoprolol, Amlodipine, Sacubitril, Nebivolol, Amlodipine, Tamsulosin, Tinidazole, Ascorbic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17226, 'Hydrochlorothiazide', 'Porfimer sodium', 'Moderate', 'Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.', 'DDInter', 'Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient''s hepatic and/or renal function.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17241/', '', 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More', 'Felodipine, Moexipril, Verapamil, Lisinopril, Perindopril, Bisoprolol, Benazepril, Trandolapril, Captopril, Azilsartan medoxomil, Nebivolol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17227, 'Hydrochlorothiazide', 'Pramlintide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17242/', '', 'Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Lisinopril, Perindopril, Bisoprolol, Benazepril, Quinapril, More', 'Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17228, 'Hydrochlorothiazide', 'Prazosin', 'Moderate', 'The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17243/', '', 'Felodipine, Olmesartan, Azilsartan medoxomil, Candesartan, Eprosartan, Sacubitril, Aliskiren, Bumetanide, Aliskiren, Tinidazole, Ascorbic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17229, 'Hydrochlorothiazide', 'Prednisolone', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', 'DDInter', 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17244/', '', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Fluocinolone acetonide, Fluorometholone, Mometasone furoate, Fluorometholone, Neomycin, More', 'Sacubitril, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Vemurafenib, Tioconazole, Furazolidone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17230, 'Hydrochlorothiazide', 'Prednisone', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', 'DDInter', 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17245/', '', 'Olsalazine', 'Sacubitril, Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Sulfamethoxazole, Sulfamethizole, Simeprevir, Vemurafenib, Econazole, Chloramphenicol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17231, 'Hydrochlorothiazide', 'Procarbazine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17246/', '', 'Sacubitril, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, Sotorasib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17232, 'Hydrochlorothiazide', 'Prochlorperazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.', 'DDInter', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17247/', '', 'Pimavanserin', 'Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17233, 'Hydrochlorothiazide', 'Procyclidine', 'Minor', 'Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17248/', '', 'Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17234, 'Hydrochlorothiazide', 'Promazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.', 'DDInter', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17249/', '', 'Pimavanserin', 'Trichlormethiazide, Sacubitril, Aliskiren, Trichlormethiazide, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17235, 'Hydrochlorothiazide', 'Promethazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', 'DDInter', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17250/', '', 'Sacubitril, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Ciclopirox, Darunavir, Tioconazole, More', 'Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17236, 'Hydrochlorothiazide', 'Propantheline', 'Minor', 'Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17251/', '', 'Papaverine, Isometheptene', 'Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17237, 'Hydrochlorothiazide', 'Propiomazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', 'DDInter', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17252/', '', 'Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Trichlormethiazide, Sacubitril, Aliskiren, Trichlormethiazide, Aliskiren, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17238, 'Hydrochlorothiazide', 'Dextropropoxyphene', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17253/', '', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', 'Trichlormethiazide, Methyclothiazide, Sacubitril, Aliskiren, Trichlormethiazide, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17239, 'Hydrochlorothiazide', 'Propranolol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', 'DDInter', 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17254/', '', 'Ivabradine, Esmolol, Carteolol, Penbutolol', 'Trandolapril, Bisoprolol, Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, Eprosartan, Aliskiren, Tinidazole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17240, 'Hydrochlorothiazide', 'Mepyramine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17255/', '', 'Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Tripelennamine, Clemastine, Tetracaine, Pheniramine, Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17241, 'Hydrochlorothiazide', 'Quetiapine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', 'DDInter', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17256/', '', 'Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Ciclopirox, Probenecid, More', 'Pimavanserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17242, 'Hydrochlorothiazide', 'Rapacuronium', 'Moderate', 'Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.', 'DDInter', 'Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17257/', '', 'Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril, Trichlormethiazide, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17243, 'Hydrochlorothiazide', 'Rasagiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17258/', '', 'Sacubitril, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 'Opicapone, Rotigotine, Tolcapone, Bromocriptine, Pergolide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17244, 'Hydrochlorothiazide', 'Remimazolam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17259/', '', 'Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17245, 'Hydrochlorothiazide', 'Repaglinide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17260/', '', 'Guar gum', 'Olmesartan, Azilsartan medoxomil, Candesartan, Eprosartan, Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Oxytetracycline, Amphotericin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17246, 'Hydrochlorothiazide', 'Reserpine', 'Moderate', 'The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17261/', '', 'Felodipine, Enalapril, Amlodipine, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17247, 'Hydrochlorothiazide', 'Riociguat', 'Moderate', 'Riociguat may potentiate the action of antihypertensive agents and other vasodilators. Symptomatic hypotension may occur. Riociguat stimulates soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system that binds with nitric oxide (NO) to catalyze the synthesis of cyclic guanosine monophosphate (cGMP). The resultant accumulation of cGMP in vascular smooth muscle cells leads to peripheral vasodilation and blood pressure decreases.', 'DDInter', 'Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17262/', '', 'Sacubitril, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 'Macitentan, Metyrosine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17248, 'Hydrochlorothiazide', 'Risperidone', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.', 'DDInter', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17263/', '', 'Pimavanserin', 'Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Darunavir, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17249, 'Hydrochlorothiazide', 'Rocuronium', 'Moderate', 'Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.', 'DDInter', 'Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17264/', '', 'Botulinum toxin type A', 'Enalapril, Moexipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril, Valsartan, Irbesartan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17250, 'Hydrochlorothiazide', 'Rofecoxib', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', 'DDInter', 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17265/', '', 'Chondroitin sulfate, Glucosamine', 'Sacubitril, Nebivolol, Tinidazole, Ascorbic acid, Simeprevir, Lactic acid, Mitapivat, Methazolamide, Vemurafenib, Darunavir, Tioconazole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17251, 'Hydrochlorothiazide', 'Rosiglitazone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17266/', '', 'Guar gum', 'Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, Eprosartan, Aliskiren, Tinidazole, Ascorbic acid, Sulfadiazine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17252, 'Hydrochlorothiazide', 'Safinamide', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17267/', '', 'Sacubitril, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, More', 'Opicapone, Rotigotine, Tolcapone, Bromocriptine, Pergolide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17253, 'Hydrochlorothiazide', 'Salmeterol', 'Moderate', 'Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.', 'DDInter', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.', 'Synergism', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17268/', '', 'Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Ipratropium, Isoprenaline', 'Trandolapril, Moexipril, Olmesartan, Azilsartan medoxomil, Candesartan, Eprosartan, Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17254, 'Hydrochlorothiazide', 'Saxagliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17269/', '', 'Felodipine, Amlodipine, Quinapril, Bisoprolol, Amlodipine, Valsartan, Irbesartan, Losartan, Olmesartan, Azilsartan medoxomil, Nebivolol, More', 'Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17255, 'Hydrochlorothiazide', 'Scopolamine', 'Minor', 'Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17270/', '', 'Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Felodipine, Moexipril, Verapamil, Ramipril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril, Valsartan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17256, 'Hydrochlorothiazide', 'Secobarbital', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17271/', '', 'Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Benazepril, Trichlormethiazide, Methyclothiazide, Sacubitril, Aliskiren, Trichlormethiazide, Aliskiren, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17257, 'Hydrochlorothiazide', 'Selegiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17272/', '', 'Sacubitril, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, More', 'Opicapone, Rotigotine, Tolcapone, Bromocriptine, Pergolide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17258, 'Hydrochlorothiazide', 'Selexipag', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', 'DDInter', 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17273/', '', 'Sacubitril, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, More', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17259, 'Hydrochlorothiazide', 'Semaglutide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17274/', '', 'Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Lisinopril, Perindopril, Bisoprolol, Benazepril, Quinapril, More', 'Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17260, 'Hydrochlorothiazide', 'Sertraline', 'Moderate', 'Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.', 'DDInter', 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17275/', '', 'Trandolapril, Olmesartan, Azilsartan medoxomil, Candesartan, Eprosartan, Sacubitril, Tinidazole, Mitapivat, Ascorbic acid, Oxytetracycline, Sulfamethizole, More', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17261, 'Hydrochlorothiazide', 'Sibutramine', 'Moderate', 'Coadministration with diuretics may potentiate the risk of hyponatremia associated with the use of selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Elderly patients and patients taking diuretics or who are otherwise volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs. Antihypertensive agents such as diuretics may potentiate the orthostatic effect that is occasionally observed upon the initiation of SSRI or SNRI therapy. Syncope and orthostatic hypotension tend to occur within the first week of SNRI/SSRI therapy but can occur at any time during treatment, particularly after a dosage increase. The use of SSRIs or SNRIs may also cause sustained increases in blood pressure and heart rate, which may antagonize the therapeutic effects of antihypertensive medications.', 'DDInter', 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hyponatremia such as nausea, vomiting, headache, malaise, lethargy, irritability, difficulty concentrating, memory impairment, confusion, weakness, muscle spasm, and unsteadiness (which may lead to falls). More severe and/or acute cases may include hallucination, syncope, seizure, coma, respiratory arrest, and death. Discontinuation of SSRI/SNRI therapy should be considered in patients who develop symptomatic hyponatremia, and appropriate medical intervention instituted as necessary. Patients should also have their blood pressure and pulse monitored before and during SSRI/SNRI therapy, especially during the first few weeks and following a dosage increase. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is recommended if SSRIs or SNRIs are prescribed in combination with diuretics, particularly in the elderly.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17276/', '', 'Felodipine, Amlodipine, Moexipril, Perindopril, Bisoprolol, Benazepril, Quinapril, Trandolapril, Fosinopril, Amlodipine, Olmesartan, More', 'Dexfenfluramine, Naltrexone, Ephedrine, Fenfluramine, Lorcaserin, Diethylpropion, Mazindol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17262, 'Hydrochlorothiazide', 'Sildenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', 'DDInter', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17277/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Vemurafenib, More', 'Sacubitril, Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, Amphotericin B, Ciclopirox, Tioconazole, Brinzolamide, Diiodohydroxyquinoline, Oxytetracycline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17263, 'Hydrochlorothiazide', 'Sitagliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17278/', '', 'Felodipine, Amlodipine, Verapamil, Bisoprolol, Quinapril, Amlodipine, Valsartan, Irbesartan, Losartan, Olmesartan, Azilsartan medoxomil, More', 'Guar gum', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17264, 'Hydrochlorothiazide', 'Nitrous acid', 'Moderate', 'Coadministration with antihypertensive agents, diuretics, vasodilators, or phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of sodium nitrite. Since sodium nitrite can cause serious hypotension and methemoglobin formation, patients may be at increased risk for complications related to inadequate perfusion and oxygenation.', 'DDInter', 'Sodium nitrite should be used with caution in the presence of concomitant antihypertensive agents, diuretics, vasodilators, or PDE5 inhibitors. Hemodynamics should be monitored during and after administration of sodium nitrite, and the infusion rate decreased if significant hypotension occurs. In addition, methemoglobin levels should be monitored and oxygen administered during treatment whenever possible.', 'Synergism', 'Sodium nitrite should be used with caution in the presence of concomitant antihypertensive agents, diuretics, vasodilators, or PDE5 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17279/', '', 'Sacubitril, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Lactic acid, Mitapivat, Amphotericin B, Clindamycin, Ciclopirox, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Cobicistat, Deferoxamine, Levoleucovorin, Arginine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17265, 'Hydrochlorothiazide', 'Sodium oxybate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17280/', '', 'Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Halothane, Thiopental, Nitrous oxide, Methohexital, Desflurane, Enflurane, Esketamine, Sevoflurane, Ketamine, Dextromethorphan, Valbenazine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17266, 'Hydrochlorothiazide', 'Solifenacin', 'Minor', 'Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17281/', '', 'Felodipine, Enalapril, Amlodipine, Moexipril, Ramipril, Lisinopril, Perindopril, Bisoprolol, Benazepril, Quinapril, Trandolapril, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Mirabegron, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, Silodosin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17267, 'Hydrochlorothiazide', 'Sotalol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', 'DDInter', 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17282/', '', 'Esmolol, Carteolol, Penbutolol, Ivabradine', 'Moexipril, Bisoprolol, Benazepril, Quinapril, Trandolapril, Fosinopril, Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17268, 'Hydrochlorothiazide', 'Succinylcholine', 'Moderate', 'Diuretics may induce hypokalemia and prolong the neuromuscular blocking effects of nondepolarizing muscle relaxants.', 'DDInter', 'Close monitoring for prolonged neuromuscular blockade, potassium replacement when indicated, and neuromuscular blocker dose adjustment is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17283/', '', 'Botulinum toxin type A', 'Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril, Valsartan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17269, 'Hydrochlorothiazide', 'Sulindac', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', 'DDInter', 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17284/', '', 'Chondroitin sulfate, Glucosamine', 'Sacubitril, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17270, 'Hydrochlorothiazide', 'Tadalafil', 'Minor', 'Based on their pharmacology, phosphodiesterase-5 (PDE5) inhibitors may conceivably potentiate the hypotensive effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17285/', '', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Mirabegron, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide, Macitentan, More', 'Sacubitril, Tinidazole, Ascorbic acid, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17271, 'Hydrochlorothiazide', 'Temazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17286/', '', 'Suvorexant, Nitrazepam, Thiopental, Butalbital, Eszopiclone, Ramelteon, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Ciclopirox, Vemurafenib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17272, 'Hydrochlorothiazide', 'Terazosin', 'Moderate', 'The hypotensive effects of thiazide diuretics and alpha-adrenergic blockers may be additive. Postural hypotension may occur.', 'DDInter', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy. Patients should be advised to take the alpha-blocker at bedtime and to notify their physician if they experience dizziness or syncope while awake.', 'Synergism', 'Hemodynamic responses should be monitored during coadministration, especially during the first few weeks of therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17287/', '', 'Olmesartan, Azilsartan medoxomil, Candesartan, Eprosartan, Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, More', 'Silodosin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17273, 'Hydrochlorothiazide', 'Terbutaline', 'Moderate', 'Coadministration with beta-2 adrenergic agonists may potentiate the hypokalemic effects of potassium-wasting diuretics. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations. Since QT prolongation is a possible side effect of beta-2 agonists, exacerbation of hypokalemia may increase the risk of torsade de pointes and other serious arrhythmias. The interaction may be more likely with systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or concomitant theophylline or corticosteroid therapy.', 'DDInter', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics. Serum potassium level and cardiovascular status should be monitored, especially if the beta-2 agonist is administered systemically or by nebulizer. Patients should be advised to notify their physician if they experience potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.', 'Synergism', 'Caution is advised when beta-2 agonists are used with potassium-wasting diuretics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17288/', '', 'Isoprenaline, Ephedrine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Ipratropium, Isoprenaline', 'Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17274, 'Hydrochlorothiazide', 'Teriparatide', 'Minor', 'The concomitant administration of hydrochlorothiazide 25 mg and teriparatide did not significantly affect serum calcium response. Urinary excretion of calcium decreased by 15% (clinically insignificant). The effect of higher doses of hydrochlorothiazide is unknown. No action is necessary.', 'DDInter', '-', 'Excretion', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17289/', '', 'Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Lisinopril, Perindopril, Bisoprolol, Benazepril, Quinapril, More', 'Abaloparatide, Parathyroid hormone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17275, 'Hydrochlorothiazide', 'Tetrabenazine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17290/', '', 'Trichlormethiazide, Methyclothiazide, Sacubitril, Aliskiren, Trichlormethiazide, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, More', 'Dextromethorphan, Valbenazine, Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17276, 'Hydrochlorothiazide', 'Tetracycline', 'Minor', 'The coadministration of diuretics and tetracyclines may result in decreased renal function manifested by increases in serum creatinine and blood urea nitrogen (BUN). Usually, no clinical intervention is necessary, unless decreases in renal function occur. If renal function deteriorates, discontinuation of one or both agents may be necessary.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17291/', '', 'Polymyxin B, Chloramphenicol, Rifamycin, Neomycin, Tinidazole, Bismuth subcitrate potassium, Rifabutin, Vonoprazan, Levofloxacin, Neomycin, Sarecycline, More', 'Felodipine, Enalapril, Moexipril, Ramipril, Perindopril, Bisoprolol, Benazepril, Trandolapril, Captopril, Fosinopril, Olmesartan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17277, 'Hydrochlorothiazide', 'Thiethylperazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', 'DDInter', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17292/', '', 'Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More', 'Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17278, 'Hydrochlorothiazide', 'Thioridazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.', 'DDInter', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17293/', '', 'Pimavanserin', 'Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17279, 'Hydrochlorothiazide', 'Thiothixene', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', 'DDInter', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17294/', '', 'Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Pimavanserin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17280, 'Hydrochlorothiazide', 'Timolol', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', 'DDInter', 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17295/', '', 'Esmolol, Carteolol, Penbutolol, Methazolamide, Neostigmine, Physostigmine, Acetylcholine, Diclofenamide, Carteolol, Brimonidine, Levobunolol', 'Moexipril, Perindopril, Bisoprolol, Trandolapril, Fosinopril, Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17281, 'Hydrochlorothiazide', 'Timolol (ophthalmic)', 'Moderate', 'Although they are often combined in clinical practice, diuretics and beta-blockers may increase the risk of hyperglycemia and hypertriglyceridemia in some patients, especially in patients with diabetes or latent diabetes. In addition, the risk of QT interval prolongation and arrhythmias (e.g. torsades de pointes) due to sotalol may be increased by potassium-depleting diuretics.', 'DDInter', 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration. Patients should be advised to seek medical assistance if they experience dizziness, weakness, fainting, fast or irregular heartbeats, or loss of blood glucose control.', 'Synergism', 'Monitoring of serum potassium levels, blood pressure, and blood glucose is recommended during coadministration.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17296/', '', 'Esmolol, Carteolol, Penbutolol, Methazolamide, Neostigmine, Physostigmine, Acetylcholine, Diclofenamide, Carteolol, Brimonidine, Levobunolol', 'Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril, Valsartan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17282, 'Hydrochlorothiazide', 'Tizanidine', 'Major', 'Tizanidine may potentiate the hypotensive effect of some medications secondary to its alpha-2 adrenergic activity. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.', 'DDInter', 'A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications. Although single doses of less than 8 mg of tizanidine have not been shown effective for spasticity in controlled clinical studies, it may be prudent to initiate treatment with 4 mg doses and gradually increase in 2 to 4 mg increments until optimum effect is achieved. The dose can be repeated at 6 to 8 hour intervals as needed, up to a maximum of three doses in 24 hours and a total daily dosage of 36 mg. However, experience with single doses exceeding 8 mg and daily doses exceeding 24 mg is limited. Close monitoring for development of hypotension is recommended.', 'Synergism', 'A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17297/', '', 'Sacubitril, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Amphotericin B, Ciclopirox, Darunavir, Probenecid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17283, 'Hydrochlorothiazide', 'Tolazamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17298/', '', 'Guar gum', 'Felodipine, Amlodipine, Verapamil, Amlodipine, Valsartan, Irbesartan, Losartan, Olmesartan, Azilsartan medoxomil, Telmisartan, Candesartan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17284, 'Hydrochlorothiazide', 'Tolbutamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17299/', '', 'Felodipine, Amlodipine, Verapamil, Amlodipine, Valsartan, Olmesartan, Azilsartan medoxomil, Telmisartan, Candesartan, Sacubitril, Aliskiren, More', 'Methacholine, Hexaminolevulinate, Secretin human, Methylene blue, Sermorelin, Sorbitol, Galactose, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17285, 'Hydrochlorothiazide', 'Tolmetin', 'Moderate', 'Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs) and diuretics may adversely affect renal function due to NSAID inhibition of the renal synthesis of prostaglandins that help maintain renal perfusion in dehydrated states. The risk may be increased in patients on dietary sodium restriction. At the same time, hypotensive effect of the diuretics may be reduced because inhibition of prostaglandins can lead to unopposed pressor activity and, consequently, elevation in blood pressure. Natriuretic and diuretic effects may also be reduced, as NSAIDs have been reported to cause sodium and water retention, which may account for the increased risk of congestive heart failure associated with the combination. NSAIDs may also increase the risk of hyperkalemia associated with potassium-sparing diuretics.', 'DDInter', 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure. If renal insufficiency or hyperkalemia develops, both drugs should be discontinued until the condition is corrected.', 'Antagonism', 'In patients receiving both diuretic and NSAID therapy, management consists of avoiding dehydration and carefully monitoring the patient''s renal function and blood pressure.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17300/', '', 'Chondroitin sulfate, Glucosamine, Tolazoline, Dimethyl sulfoxide', 'Sacubitril, Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17286, 'Hydrochlorothiazide', 'Tolterodine', 'Minor', 'Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17301/', '', 'Trandolapril, Olmesartan, Azilsartan medoxomil, Candesartan, Eprosartan, Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, More', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Mirabegron, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17287, 'Hydrochlorothiazide', 'Topiramate', 'Moderate', 'Coadministration with thiazide-like diuretics, such as hydrochlorothiazide, may enhance the hypokalemic effects and increase the serum concentrations of topiramate. The mechanism for this interaction has not been delineated.', 'DDInter', 'Until more information is available, caution is advised if topiramate is administered with a thiazide-like diuretic, such as hydrochlorothiazide. Dosage adjustments as well as clinical and laboratory monitoring of topiramate should be considered whenever a thiazide-like diuretic is added to or withdrawn from therapy. Serum potassium levels should also be monitored during concomitant therapy. Patients should be observed for the development of topiramate adverse effects.', 'Others', 'Until more information is available, caution is advised if topiramate is administered with a thiazide-like diuretic, such as hydrochlorothiazide.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17302/', '', 'Brivaracetam, Ezogabine, Cenobamate, Methylphenobarbital, Ethosuximide, Lacosamide, Ethotoin, Rufinamide, Paramethadione, Perampanel, Ganaxolone, More', 'Trandolapril, Fosinopril, Bisoprolol, Olmesartan, Azilsartan medoxomil, Nebivolol, Candesartan, Sacubitril, Aliskiren, Eprosartan, Aliskiren, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17288, 'Hydrochlorothiazide', 'Toremifene', 'Moderate', 'Drugs that decrease renal calcium excretion, such as the thiazide diuretics, may increase the risk of hypercalcemia in patients receiving toremifene.', 'DDInter', 'Monitoring of calcium levels is recommended. Toremifene should be discontinued if severe hypercalcemia occurs. Patients should be advised to notify their physician if they experience potential symptoms of hypercalcemia such as lethargy, somnolence, confusion, headache, seizures, ataxia, weakness, muscle pain, irregular heartbeat, anorexia, thirst, or polyuria.', 'Excretion', 'Monitoring of calcium levels is recommended.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17303/', '', 'Darolutamide, Aminoglutethimide, Abarelix, Flutamide, Enzalutamide, Relugolix, Degarelix, Nilutamide, Apalutamide, Abiraterone', 'Felodipine, Enalapril, Amlodipine, Moexipril, Ramipril, Lisinopril, Perindopril, Bisoprolol, Benazepril, Quinapril, Trandolapril, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17289, 'Hydrochlorothiazide', 'Torasemide', 'Moderate', 'The combination of a thiazide and loop diuretic may produce additive or synergistic effects on diuresis and excretion of electrolytes including sodium, potassium, magnesium, and chloride. Although these agents may be combined therapeutically in some patients with inadequate response to a single agent, the increased risk of dehydration, hypotension, hypokalemia, hypomagnesemia, and hyponatremia should be recognized.', 'DDInter', 'Caution is advised during concomitant use of a thiazide and loop diuretic. Dosages should be titrated slowly and carefully, and electrolytes, BUN, fluid status, blood pressure, and renal function should be monitored regularly. Patients should be advised to contact their physician if they experience signs and symptoms of fluid and electrolyte depletion such as dizziness, lightheadedness, dry mouth, thirst, fatigue, weakness, lethargy, muscle cramps, decreased urination, postural hypotension, and tachycardia.', 'Synergism', 'Caution is advised during concomitant use of a thiazide and loop diuretic.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17304/', '', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Trichlormethiazide, Vemurafenib, More', 'Olmesartan, Azilsartan medoxomil, Candesartan, Eprosartan, Sacubitril, Tinidazole, Ascorbic acid, Simeprevir, Lactic acid, Mitapivat, Methazolamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17290, 'Hydrochlorothiazide', 'Tranylcypromine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', 'DDInter', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17305/', '', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Sacubitril, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17291, 'Hydrochlorothiazide', 'Trazodone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17306/', '', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Felodipine, Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17292, 'Hydrochlorothiazide', 'Treprostinil', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', 'DDInter', 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17307/', '', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, More', 'Sacubitril, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Amphotericin B, Clindamycin, Ciclopirox, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17293, 'Hydrochlorothiazide', 'Triamcinolone', 'Moderate', 'The concomitant use of corticosteroids and agents that deplete potassium (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may result in increased risk of hypokalemia. Corticosteroids can produce hypokalemia and other electrolyte disturbances via mineralocorticoid effects, the degree of which varies with the agent and route of administration (i.e. systemic vs. local).', 'DDInter', 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given. Potassium supplementation may be necessary. Patients should be advised to notify their physician if they experience signs of electrolyte disturbances such as weakness, lethargy, and muscle pains or cramps.', 'Synergism', 'Patients receiving potassium-depleting agents with corticosteroids should be monitored closely for development of hypokalemia, particularly if fludrocortisone or large doses of another corticosteroid or adrenocorticotropic agent is given.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17308/', '', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Ciclesonide, Mometasone furoate, Mometasone, Vitamin A, Ephedrine, More', 'Sacubitril, Tinidazole, Ascorbic acid, Simeprevir, Lactic acid, Mitapivat, Vemurafenib, Probenecid, Tioconazole, Furazolidone, Diiodohydroxyquinoline, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17294, 'Hydrochlorothiazide', 'Trifluoperazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.', 'DDInter', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17309/', '', 'Pimavanserin', 'Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17295, 'Hydrochlorothiazide', 'Triflupromazine', 'Moderate', 'Some neuroleptic agents may cause prolongation of the QT interval. While clinical data are lacking, the coadministration of other agents that can produce hypokalemia and/or hypomagnesemia (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins, stimulant laxatives) may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes. In addition, neuroleptic agents may potentiate the hypotensive effect of diuretics secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during the initial dose titration period of neuroleptic therapy.', 'DDInter', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances. Serum electrolytes should be monitored and any abnormalities corrected prior to initiating therapy with a neuroleptic. Close clinical monitoring for development of hypotension is recommended if neuroleptic agents are prescribed with a diuretic medication. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. A lower starting dosage and slower titration of the neuroleptic agent may be appropriate in patients receiving antihypertensive therapy, especially if they are elderly.', 'Synergism', 'Caution is advised when neuroleptics must be used concomitantly with medications that can cause potassium and/or magnesium disturbances.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17310/', '', 'Pimavanserin', 'Trichlormethiazide, Sacubitril, Aliskiren, Trichlormethiazide, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17296, 'Hydrochlorothiazide', 'Trihexyphenidyl', 'Minor', 'Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17311/', '', 'Felodipine, Moexipril, Verapamil, Ramipril, Perindopril, Benazepril, Trandolapril, Captopril, Fosinopril, Olmesartan, Azilsartan medoxomil, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17297, 'Hydrochlorothiazide', 'Alimemazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', 'DDInter', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17312/', '', 'Trichlormethiazide, Sacubitril, Aliskiren, Trichlormethiazide, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, More', 'Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17298, 'Hydrochlorothiazide', 'Trimipramine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', 'DDInter', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17313/', '', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Sacubitril, Aliskiren, Aliskiren, Tinidazole, Ascorbic acid, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17299, 'Hydrochlorothiazide', 'Troglitazone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17314/', '', 'Guar gum', 'Enalapril, Moexipril, Ramipril, Lisinopril, Perindopril, Bisoprolol, Benazepril, Quinapril, Trandolapril, Captopril, Fosinopril, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (17300, 'Hydrochlorothiazide', 'Trospium', 'Minor', 'Anticholinergic agents may increase the absorption and oral bioavailability of thiazide diuretics. The proposed mechanism involves increased gastrointestinal transit time due to reduction of stomach and intestinal motility by anticholinergic agents.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/17315/', '', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Mirabegron, Yohimbine, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, More', 1767369485);
